These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Atypical Hemolytic Uremic Syndrome After Kidney Transplantation: Lessons Learned From the Good, the Bad, and the Ugly. A Case Series With Literature Review. Fayek SA; Allam SR; Martinez E; Pan G; Dao A; Rofaiel G Transplant Proc; 2020; 52(1):146-152. PubMed ID: 31924403 [TBL] [Abstract][Full Text] [Related]
28. Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report. Bahougne T; Olagne J; Munch M; Braun-Parvez L; Chenard MP; Frémeaux-Bacchi V; Caillard S; Baltzinger P; Greget M; Kessler L; Moulin B BMC Nephrol; 2020 Sep; 21(1):405. PubMed ID: 32950058 [TBL] [Abstract][Full Text] [Related]
29. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125 [TBL] [Abstract][Full Text] [Related]
31. Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Provaznikova D; Rittich S; Malina M; Seeman T; Marinov I; Riedl M; Hrachovinova I Pediatr Nephrol; 2012 Jan; 27(1):73-81. PubMed ID: 21706448 [TBL] [Abstract][Full Text] [Related]
32. Case report: Eculizumab plus obinutuzumab induction in a deceased donor kidney transplant recipient with DEAP-HUS. Favi E; Molinari P; Alfieri C; Castellano G; Ferraresso M; Cresseri D Front Immunol; 2022; 13():1073808. PubMed ID: 36591301 [TBL] [Abstract][Full Text] [Related]
33. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens. Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893 [TBL] [Abstract][Full Text] [Related]
34. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480 [TBL] [Abstract][Full Text] [Related]
35. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. Gonzalez Suarez ML; Thongprayoon C; Mao MA; Leeaphorn N; Bathini T; Cheungpasitporn W J Clin Med; 2019 Jun; 8(7):. PubMed ID: 31252541 [TBL] [Abstract][Full Text] [Related]
36. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era. Avila Bernabeu AI; Cavero Escribano T; Cao Vilarino M Nephron; 2020; 144(11):537-549. PubMed ID: 32950988 [TBL] [Abstract][Full Text] [Related]
37. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience. Kant S; Bhalla A; Alasfar S; Alachkar N BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487 [TBL] [Abstract][Full Text] [Related]
38. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system]. Frémeaux-Bacchi V; Fakhouri F; Roumenina L; Dragon-Durey MA; Loirat C Rev Med Interne; 2011 Apr; 32(4):232-40. PubMed ID: 21376430 [TBL] [Abstract][Full Text] [Related]
39. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452 [TBL] [Abstract][Full Text] [Related]
40. Compound Haplotype Variants in Furmańczyk-Zawiska A; Kubiak-Dydo A; Użarowska-Gąska E; Kotlarek-Łysakowska M; Salata K; Kolanowska M; Świerniak M; Gaj P; Leszczyńska B; Daniel M; Jażdżewski K; Durlik M; Wójcicka A J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33920896 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]